NEXMED DEVELOPING TREATMENT FOR PREMATURE EJACULATION.
As presented at the 2003 Annual Meeting of the American Urological Association, NexMed conducted a three-month, multi-center, single-blind pilot study for which fifty-one PE patients (mean age 37.7 years and PE duration of 4.5 years) were recruited. Eight patients were enrolled in the control (alprostadil) cream group and 43 patients were enrolled in the study (alprostadil/lidocaine/NexACT) cream group. The primary efficacy variable was ejaculatory latency time (ELT). The secondary efficacies include the degree of satisfaction of both patient and partner, as well as physician assessment of clinical efficacy.
In the control group, only 12.5% patients, after administration of the cream, had a mean ELT over 2 minutes, and no satisfaction was reported from either patients or their partners. In the alprostadil/lidocaine/NexACT cream treatment group, the ELT increased to more than 2 minutes in 53.5% of all patients. The sexual satisfaction, as assessed by the patients and their partners, reached 72.1% and 67.4%, respectively. The clinical efficacy was 72.1% as assessed by the doctors. All reported adverse events were mild and transient.
NexMed recently completed a second proof of concept study, which was a multi-center, double-blind, crossover, at-home use trial. The data are currently being reviewed and analyzed. Both studies were conducted overseas.
Ming Qi Lu, MD, Ph.D., NexMed's director of Exploratory Development, commented, "The results from the two studies suggest that our proprietary product under development has the potential to become an effective treatment for PE. We look forward to undertaking additional development of this product in the U.S. and abroad."
About NexMed, Inc.
NexMed, Inc. is an emerging pharmaceutical and medical technology company, with a product pipeline of innovative topical drug treatments based on the NexACT transdermal delivery technology. Its lead NexACT product under development is the Alprox-TD cream treatment for male erectile dysfunction. NexMed is also working with various pharmaceutical companies to explore the introduction of its NexACT delivery system into their existing drugs as a means of developing new patient-friendly transdermal products and extending patent lifespans.
For more information, call 212/983-1702 ext. 209 or visit http://www.nexmed.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 1, 2003|
|Previous Article:||TRANSFORM DEVELOPING IN VITRO CELL CONTROL METHODOLOGY.|
|Next Article:||FDA CLEARS SANGSTAT'S TWO HYMOGLOBULIN IND APPLICATIONS.|